Effect of catheter ablation on clinical outcomes in patients with atrial fibrillation and significant functional mitral regurgitation

Jin-Tao Wu*, Dan-Qing Zhao, Fu-Tao Zhang, Xiao-Jie Liu, Juan Hu, Lei-Ming Zhang, Xian-Wei Fan, Hai-Tao Yang, Li-Jie Yan, Jing-Jing Liu and Shan-Ling Wang

Abstract

Background: In patients with atrial fibrillation (AF) and functional mitral regurgitation (MR), catheter ablation reduces the severity of MR and improves cardiac remodeling. However, its effects on prognosis are uncertain.

Methods: This retrospective study included 151 consecutive patients with AF and functional MR, 82 (54.3%) of whom were treated by catheter ablation (Ablation group) and 69 (45.7%) with drug therapy without ablation (Non-ablation group). Forty-three pairs of these patients were propensity matched on the basis of age, CHA2DS2-VASc scores, and left ventricular ejection fraction. The primary outcome evaluated was severity of MR, cardiac remodeling and the combined incidence of subsequent heart failure-related hospitalization and strokes/transient ischemic attacks.

Results: Patients in the Ablation group showed a significant decrease in the severity of MR ($p < 0.001$), a significant decrease in the left atrial diameter ($p = 0.010$), and significant improvement in the left ventricular ejection fraction ($p = 0.015$). However, patients in the Non-ablation group showed only a significant decrease in the severity of MR ($p = 0.004$). The annual incidence of the studied events was 4.9% in the Ablation group and 16.7% in the Non-ablation group, the incidence being significantly lower in the ablation than Non-ablation group ($p = 0.026$) according to Kaplan–Meier curve analyses. According to multivariate Cox regression analysis, catheter ablation therapy (hazard ratio [HR] 0.27, 95% confidence interval [CI] 0.09–0.84; $p = 0.024$) and heart failure at baseline (HR 3.84, 95% CI 1.07–13.74; $p = 0.038$) were independent predictors of the incidence of the studied events.

Conclusions: Among patients with AF and functional MR, catheter ablation was associated with a significantly lower combined risk of heart failure-related hospitalization and stroke than in a matched cohort of patients receiving drug therapy alone.

Keywords: Atrial fibrillation, Catheter ablation, Functional mitral regurgitation, Drug therapy

Background

Atrial fibrillation (AF) and functional mitral regurgitation (MR) frequently coexist and exacerbate each other [1, 2]. The combination of these two conditions increases affected patients’ cardiovascular mortality and hospitalization rates [3], indicating an urgent need for developing effective therapies for these patients. Simultaneous treatment of AF and MR is ideal. However, surgical therapy is not recommended for treatment of isolated refractory AF [4]. Additionally, many patients with functional MR are not referred for mitral valve surgery because of a high surgical risk or comorbidities and a lack of proven mortality benefit [5, 6]. Catheter ablation is currently considered the treatment of choice...
for symptomatic drug-refractory AF [4]. Catheter ablation of AF in patients with functional MR is reportedly very effective in reducing the severity of MR [2, 7] and improving cardiac remodeling [7]. However, to the best of our knowledge, no study has assessed the effect of catheter ablation of AF on the prognosis of this particular subset of patients. Therefore, the present study was performed to compare clinical outcomes among patients with AF who had developed functional MR and underwent catheter ablation versus those treated with medical therapy only and to evaluate the effect of catheter ablation of AF on the prognosis of these patients.

Methods

Patients

Consecutive patients with AF who had been hospitalized in Henan Provincial People’s Hospital for diagnosis and treatment between January 2018 and December 2019 were retrospectively reviewed. Reports of transthoracic echocardiograms that had been performed before deciding on a treatment strategy were screened. MR was defined as functional if leaflets showed normal morphology but did not properly coapt because of either left ventricular (LV) or left atrial (LA) dilatation [8]. Functional MR was classified as either absent or as mild, moderate, or severe MR [8]. Moderate and severe MR were considered significant in the present study. The inclusion criteria were (a) age of < 80 years, (b) moderate or severe MR, (c) LA diameter of < 55 mm, and (d) LV ejection fraction (LVEF) of ≥ 35%. The exclusion criteria were (a) previous AF ablations; (b) previous cardiac surgery or congenital heart disease; and (c) primary MR (mitral valve prolapse, rheumatic disease, endocarditis, previous papillary muscle rupture, or abnormalities in mitral valve leaflets or chordae). We divided patients into two groups according to catheter ablation therapy status, the Ablation group comprising patients who had undergone AF ablation and the Non-ablation group comprising patients who had undergone only conventional drug therapy and not AF ablation. Whether or not to perform AF ablation was decided in accordance with the patient’s preference and the operator’s discretion. Propensity-matching techniques were then used to select two subsets of patients that were as similar as possible for outcomes analysis. The study complied with the Declaration of Helsinki and the study protocol was approved by the local Institutional Review Board.

Catheter Ablation strategy

Patients in the Ablation group had undergone AF ablation. After obtaining written informed consent, ablation was performed with the patient in a post-absorptive state under conscious sedation. Intravenous heparin was administered during the procedure, doses being adjusted to achieve an activation clotting time of > 300 ms.

The CARTO 3-dimensional electro-anatomical mapping system (Biosense Webster, Diamond Bar, CA, USA) was used in the majority of procedures. Ablation techniques varied according to the operator’s discretion, anatomical features, and type of AF. Techniques included ipsilateral pulmonary vein isolation (PVI) and modification of the atrial substrate by mapping and ablation of complex fractionated atrial electrograms (CFAEs), the cavitricuspid isthmus, and/or additional LA linear ablation, such as of the roof line, posterior box lesion, or mitral valve line from the annulus to the inferior pulmonary vein (PV) [7]. During PVI, we used the technique of circumferential PV ablation guided by three-dimensional LA mapping, which has previously been described in detail [9]. Briefly, the LA was explored via a trans-septal approach. The LA geometry was reconstructed with a 3.5-mm tip Thermocool SmartTouch catheter (Biosense Webster) in a CARTO 3-dimensional electro-anatomical mapping system. Continuous irrigated radiofrequency ablation was performed along each PV antrum to encircle the ipsilateral PVs. Ablation was delivered point by point with Thermocool SmartTouch catheters in power-controlled mode at 35 W. The target ablation index was 380 to 400 for the LA posterior wall and 500 elsewhere. The target temperature was 43 °C, and the infusion rate was 17 mL/min. The procedural endpoints were completeness of continuous circular lesions and electrical isolation of all PVS identified by a decapolar circumferential mapping catheter (Lasso; Biosense Webster).

Guideline-directed medical therapy

Patients in the Non-ablation group had undergone conventional medical treatment but not ablation during the follow-up period. Their attending physicians had selected their medications in accordance with published guidelines [5, 10]. Medications included rate control agents (B-blockers, non-dihydropyridine calcium channel blockers, and digoxin), antiarrhythmic drugs, and anticoagulants.

Patient follow-up

The primary clinical outcomes evaluated were the combined incidence of adverse events, including heart failure-related hospitalization or stroke/transient ischemic attack (TIA). All study patients were followed up until one of these events had occurred or until December 2020, whichever came first. All of them were contacted by telephone every 6 months and the participants or their relatives or carers interviewed regarding occurrence of any interval target clinical events. For all reported events, medical records were retrieved and reviewed.
failure-related hospitalization was defined as hospital admission for advanced symptoms of heart failure. Stroke was defined as a permanent neurological disability or impairment caused by various types of hemorrhagic and ischemic strokes [11]. TIA was diagnosed in accordance with the World Health Organization criteria [12], namely rapidly developing clinical evidence of focal or global disturbance of cerebral function, lasting less than 24 h, and with no apparent non-vascular cause. Subsequent echocardiographic follow-up was performed in our institution or in the patient's home institution. Recurrence of AF was defined as occurrence of confirmed atrial tachyarrhythmia lasting longer than 30 s (documented by ECG or Holter recordings) more than 3 months after catheter ablation [10].

Statistical analysis
All analyses were performed using SPSS software version 24.0 (IBM Corp., Armonk, NY, USA). Continuous variables are presented as mean± standard deviation, and discrete variables are presented as percentages. Comparisons between variables were made using unpaired independent-samples t-tests for continuous variables, and the Mann–Whitney U-test for discrete variables. Categorical variables are presented as numbers and percentages of the group total and were compared using the χ² test or Fisher's exact test as appropriate. Patient characteristics appeared well balanced between groups, the only statistically significant difference between them being the LA diameter.

AF Ablation efficacy outcome
PVI was achieved in all patients in the Ablation group during the initial procedure. A cavotricuspid isthmus line was created in 27 (62.8%) patients and CFAEs were also ablated during the first procedure in 18 (41.9%) patients. Thirty (69.8%) patients had additional LA linear ablation. There were no procedural complications in the Ablation group. During the mean follow-up period of 16.7±10.2 months (range 3–35 months), 20 patients (46.5%) developed recurrences of AF. Only two patients underwent repeat procedures over the entire follow-up period.

Follow-up echocardiography
Follow-up echocardiograms were available in 53 of the 86 patients at a mean of 8.6±6.6 months after the initial procedure. Of these 53 patients, 35 were in the Ablation group and 18 were in the Non-ablation group. Patients in the Ablation group showed a significant decrease in the severity of MR (p<0.001), a significant decrease in the LA diameter (p=0.010), and significant improvement in the LVEF (p=0.015) compared with baseline. However, they showed no significant difference in the LV end-diastolic dimension (p=0.621) or LV end-systolic dimension (p=1.000) compared with baseline (Figs. 1, 2). Patients in the Non-ablation group showed a significant decrease in the severity of MR (p=0.004), but there were no significant differences in the LV end-diastolic dimension (p=0.957), LV end-systolic dimension (p=0.484), LA diameter (p=0.509), or LVEF (p=0.849) (Figs. 1, 2).
Comparison of clinical outcomes
The mean follow-up duration in the Ablation and Non-ablation group was 22.6 ± 8.1 and 20.1 ± 9.6 months, respectively. During the entire follow-up period, heart failure-related hospitalization was required by four patients (9.3%) in the Ablation group. There were no stroke or TIA events in this group. Thus, only four patients (9.3%) in the Ablation group had a target clinical event, namely heart failure-related hospitalization or new-onset stroke. In contrast, 11 patients (25.6%) in the Non-ablation group had heart failure-related hospitalization and one had a stroke event. Thus, target clinical events occurred in 12 patients (27.9%) in the Non-ablation group. The overall annual rate of heart failure-related hospitalization was 4.9% in the Ablation group and 15.3% in the Non-ablation group (Fig. 3B). The overall annual rate of stroke or TIA was 0% in the Ablation group and 1.4% in the Non-ablation group (Fig. 3C). The combined overall annual rate of target clinical events was 4.9% in the Ablation group and 16.7% in the Non-ablation group (Fig. 3A). Kaplan–Meier curves for the combined incidence of target clinical events showed that event-free rates were significantly higher in the Ablation than the Non-ablation group (p = 0.026) (Fig. 4).

Predictors of the incidence of clinical events
Predictors of the incidence of target clinical events in the entire patient cohort were determined using a Cox proportional hazards model. Univariable Cox analysis showed that catheter ablation therapy (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.10–0.94; p = 0.038) was associated with the occurrence of target clinical events (Table 2). According to multivariate analysis, catheter ablation therapy (HR 0.27, 95% CI 0.09–0.84; p = 0.024) and heart failure at baseline (HR 3.84, 95% CI 1.07–13.72; p = 0.039) were independent predictors of the incidence of target clinical events (Table 2).

Discussion
The main findings in this study were as follows: (1) in patients with AF and significant functional MR, catheter ablation is associated with a significantly lower risk
of target clinical events (heart failure-related hospitalization, stroke, and TIA) than is conventional drug therapy. (2) In these patients, catheter ablation reduces the severity of MR and improves cardiac remodeling.

A previous study evaluating the prognostic significance of residual functional MR in hospitalized patients with chronic AF and heart failure but a preserved LVEF showed that after optimized drug therapies, the mean MR grade at discharge was significantly lower than that during hospitalization [13]. These findings suggest that conventional drug therapy alone may significantly reduce the severity of MR in patients with AF and functional MR, which is supported by our finding that patients in the Non-ablation group showed a significant decrease in the severity of MR during the follow-up period compared with baseline. In addition, several studies have examined the efficacy of catheter ablation of AF in patients with MR. A study retrospectively compared 53 patients with significant functional MR and normal LV systolic function (LVEF ≥ 50%) with a matched AF cohort with trivial and/or mild MR during first AF ablation [2]. This previous study showed that successful ablations were associated with a significant reduction in severity of MR and LA size. In a recent study investigating the outcomes of catheter ablation of AF in a subgroup of patients presenting with functional MR and LV systolic dysfunction, we also found associations between freedom from recurrent atrial tachyarrhythmia after ablation and a reduction in severity of MR and with positive LA and LV remodeling [7]. Our findings suggest that, similarly to patients with
AF with functional MR and normal LV function, patients with AF with functional MR and LVSD also benefit from restoration of sinus rhythm by catheter ablation of AF. However, whether catheter ablation is more beneficial than conventional drug therapy in improving clinical outcomes in patients with AF and functional MR is unclear.

In this comparative study of catheter ablation versus medical therapy in patients with AF and functional MR, we found lower annual overall rates of target clinical events in the Ablation than in the Non-ablation group. According to univariate and multivariate analyses, catheter ablation therapy is significantly associated with fewer subsequent target clinical events, namely heart failure-related hospitalization and strokes/TIA. Our findings suggest that the rates of clinical outcomes may be more effectively reduced by catheter ablation than by conventional drug therapy in patients with AF and functional MR. This may be explained by our finding that besides a significant reduction in the severity of MR in the two groups, patients in the Ablation group also showed a significant decrease in the LA diameter and improvement in the LVEF whereas patients in the Non-ablation group did not.

Fig. 2 Change in A, B left ventricular dimensions, C left atrial diameter, and D left ventricular ejection fraction from baseline to follow-up. LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LAD, left atrial diameter; LVEF, left ventricular ejection fraction.
In our previous study, we showed that freedom from recurrent AF is associated with a reduction in the severity of MR and positive cardiac reverse remodeling, whereas patients with AF recurrence after AF ablation do not experience these benefits [7]. These findings suggest that maintenance of sinus rhythm after ablation is important in achieving reduction in the severity of MR and positive cardiac reverse remodeling, and may be associated with subsequent better clinical outcomes. However, AF patients with functional MR have high recurrence rates after AF ablation [14]. A previous study of 216 patients with long-standing persistent AF who underwent catheter ablation identified both MR and LA size as independent predictors of recurrence of AF [15]. In the current study, we found a 46.5% rate of recurrence of AF during a mean follow-up period of 16.7 ± 10.2 months after a single ablation procedure. Because the rates of recurrence of AF after ablation are higher with longer term follow-up, whether catheter ablation is still associated with a lower risk of clinical events than conventional drug therapy during longer term follow-up is unknown. Therefore, further studies incorporating long-term follow-up are required for these patients.

Among patients with AF and functional MR, some have normal LV systolic function, in which functional MR develops as a result of LA dilatation. This MR is known as atrial functional MR [16]. However, in present study, we did not stratify patients with atrial functional MR or functional MR secondary to LV dilatation for two reasons. First, atrial functional MR is not well understood and is still under evaluation. The definition of “atrial functional MR” is yet not widely adopted. Second, because AF can also result in LV systolic dysfunction due to loss of atrioventricular synchrony or can be a direct cause of tachycardia-induced ventricular cardiomyopathy, patients with AF and functional MR usually have LV dilatation. Additionally, LV dilatation can precede functional MR and AF because pre-existing ventricular cardiomyopathy can result in subsequent functional MR and atrial dilatation, which increase the likelihood of AF development [17, 18]. Thus, for the majority of patients with AF co-existent with LV dilatation and functional MR, the mechanism of MR usually includes both LV and LA dilatation, and it is difficult to differentiate the mechanism of MR from LV dilatation or LA dilatation.

Several limitations of our study should be considered. First, the small sample size is a major limitation of this
study and may have introduced statistical bias. Further studies with larger sample sizes are needed. Second, because there were multiple differences at baseline between the Ablation and Non-ablation groups, propensity-matching techniques were used in this study. Because the sample size was small, we did not match all of the differences between the two groups. The patients’ age [19], CHA2DS2-VASc scores [20], and LVEF [21, 22] were significantly associated with the target clinical events (heart failure-related hospitalization or strokes/TIA); therefore, the patients were propensity score-matched on the basis of these three parameters. Fortunately, the patient characteristics appeared well balanced between the two groups after matching; the only statistically significant difference between them was the LA diameter. However, multivariable Cox analysis showed that the LA diameter was not an independent predictor of the target clinical events, suggesting that this bias would not have affected our conclusions. Third, for patients with persistent AF, we performed ipsilateral PVI and atrial substrate modification. However, different patients may have been treated by different techniques of atrial substrate modification according to the operator’s discretion and patients’ clinical features, and this may have introduced bias. Notably, the current guidelines contain no consensus regarding the techniques of atrial substrate modification for persistent AF [4]. Further prospective studies in which the same atrial substrate modification techniques are used may be required. Fourth, follow-up echocardiograms were available in only 53 of the 86 patients, including 81.4% (35/43) patients in the Ablation group and 41.9% (18/43) patients in the Non-ablation group. Although this may not have affected our findings in the Ablation group, the findings regarding the severity of MR and cardiac remodeling in the Non-ablation group are not convincing because follow-up echocardiograms were available only in 41.9% (18/43) of patients. However, a previous study showed that conventional drug therapy alone may significantly reduce the severity of MR in patients with AF and functional MR [13], which supports our findings in the Non-ablation group. Further studies are required to clarify our findings. Fifth, we did not assess differences in quality of life associated with long-term drug therapy or ablation between the two study groups because these measures are not routinely captured in medical records. Finally, the generalizability

| Univariate Cox regression | Multivariate Cox regression |
|---------------------------|-----------------------------|
| **Univariate Cox regression** | **Multivariate Cox regression** |
| **HR** | **95% CI** | **P value** | **HR** | **95% CI** | **P value** |
| Age | 1.03 | 0.97–1.10 | 0.303 | 3.84 | 1.07–13.74 | 0.038 |
| Female | 1.16 | 0.43–3.13 | 0.763 | | | |
| Body mass index | 1.08 | 0.94–1.24 | 0.288 | | | |
| AF duration | 1.01 | 1.00–1.02 | 0.172 | | | |
| Persistent AF | 2.37 | 0.54–10.45 | 0.254 | | | |
| CHA2DS2-VASc score | 1.28 | 0.97–1.68 | 0.085 | | | |
| Diabetes mellitus | 0.83 | 0.24–2.91 | 0.767 | | | |
| Hypertension | 1.30 | 0.48–3.49 | 0.609 | | | |
| Previous stroke or TIA | 2.16 | 0.78–5.94 | 0.137 | | | |
| Heart failure | 3.01 | 0.86–10.58 | 0.086 | | | |
| Coronary artery disease | 1.22 | 0.44–3.35 | 0.702 | | | |
| Chronic kidney disease | 2.65 | 0.60–11.78 | 0.199 | | | |
| LVEF | 0.99 | 0.94–1.04 | 0.718 | | | |
| LA diameter | 1.04 | 0.94–1.15 | 0.420 | | | |
| LVESD | 1.02 | 0.95–1.09 | 0.621 | | | |
| LVEDD | 1.02 | 0.95–1.10 | 0.606 | | | |
| Anticoagulants | 2.57 | 0.73–9.01 | 0.141 | | | |
| β-blockers | 1.92 | 0.54–6.77 | 0.313 | | | |
| Antiarrhythmics (Class I or III) | 1.06 | 0.30–3.75 | 0.923 | | | |
| Calcium channel blockers | 0.69 | 0.16–3.04 | 0.624 | | | |
| Digoxin | 1.03 | 0.33–3.18 | 0.966 | | | |
| Catheter ablation therapy | 0.30 | 0.10–0.93 | 0.037 | 0.27 | 0.09–0.84 | 0.024 |

AF, atrial fibrillation; TIA, transient ischemic attacks; LVEF, left ventricular ejection fraction; LA, left atrial; LVEDD, left ventricular end-diastolic dimensions; LVESD, left ventricular end-systolic dimensions; HR, hazard ratio; CI, confidence interval.
of our findings may be limited by the single-center, retrospective, observational approach.

**Conclusions**

Among patients with AF and functional MR, catheter ablation is associated with a significantly lower risk of clinical events than is conventional drug therapy. These findings require confirmation with randomized study designs and long-term follow up.

**Abbreviations**

AF: Atrial fibrillation; CFAEs: Complex fractionated atrial electrograms; CI: Confidence interval; HR: Hazard ratio; LA: Left atrial; LV: Left ventricular; LVEF: LV ejection fraction; MR: Mitral regurgitation; PV: Pulmonary vein; PVI: Pulmonary vein isolation; TIA: Transient ischemic attack.

**Acknowledgements**

We thank Dr Trish Reynolds, MBBS, FRACP, from Liwen Bianji (Edanz) (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

**Authors’ contributions**

JTW conceived and coordinated the study, designed, performed and analyzed the experiments, wrote the paper. DQZ, FTZ, XIL, JH, LMZ, XWF, HTY, LJY, JLL and SLW carried out the data collection, data analysis, and revised the paper. All authors read and approved the final manuscript.

**Funding**

This research was supported by Medical Science and Technology Project of Henan Province (No. SBGJ202002030) and Science and Technology Research Project of Henan Province (No. 212102310793). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

The data set supporting the results of this article are included within the article, further inquiries can be directed to the corresponding author/s.

**Declarations**

**Ethics approval and consent to participate**

The study complied with the Declaration of Helsinki and the study protocol was approved by the local Institutional Review Board of Henan University People’s Hospital, Henan Provincial People’s Hospital. Informed consent was waived by the committee because of the retrospective nature of the study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that there is no competing interests.

**Received:** 17 June 2021  **Accepted:** 22 November 2021  **Published online:** 07 December 2021

**References**

1. Kim DH, Heo R, Handschumacher MD, Lee S, Choi YS, Kim KR, Shin Y, Park HK, Birchoff J, Akikawa E, et al. Mitral valve adaptation to isolated annular dilatation: insights into the mechanism of atrial functional mitral regurgitation. JACC Cardiovasc Imaging. 2019;12(4):665–77.

2. Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. J Am Coll Cardiol. 2011;58(14):1474–81.

3. Abe Y, Akamatsu K, Ito K, Matsumura Y, Shimeno K, Naranu T, Takahashi Y, Shibata T, Yoshiyama M. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ J. 2018;82(5):1451–8.

4. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aquinaga L, Akar JG, Badhwar V, Brugada J, Camm J, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLACE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1–160.

5. Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Muhoz DR, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardio-Thorac Surg. 2017;52(4):616–64.

6. Tozzi P. The future of functional mitral regurgitation treatment. Eur Heart J. 2019;40(27):2215–7.

7. Wu JT, Zaman JAB, Yakupoglu HY, Vennelly B, Emily C, Nabeela K, Jarman J, Haldar S, Jones DG, Wajid H, et al. Catheter ablation of atrial fibrillation in patients with functional mitral regurgitation and left ventricular systolic dysfunction. Front Cardiovasc Med. 2020;7:596491.

8. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, Hagendorff A, Monin JL, Badano L, Zamorano JL. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11(4):307–32.

9. Wu J, Fan J, Yang H, Yan L, Xu X, Duan H, Wang S, Chu Y. Usefulness of a low resting heart rate to predict recurrence of atrial fibrillation after catheter ablation in people ≥65 years of age. Am J Cardiol. 2018;122(1):97–101.

10. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.

11. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(7):2064–89.

12. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol. 1988;41(2):105–14.

13. Ito K, Abe Y, Watanabe H, Shimada Y, Shibayama K, Oe H, Hyodo E, Miyazaki C, Takahashi Y, Shibata T, et al. Prognostic significance of residual functional mitral regurgitation in hospitalized heart failure patients with chronic atrial fibrillation and preserved ejection fraction after medical therapies. J Echocardiogr. 2019;17(4):197–205.

14. Gertz ZM, Raina A, Mountantonakis SE, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE. The impact of mitral regurgitation on patients undergoing catheter ablation of atrial fibrillation. Europace. 2011;13(8):1127–32.

15. Zhao L, Jiang W, Zhou L, Gu J, Wang Y, Liu Y, Zhang X, Wu S, Liu X. The role of valvular regurgitation in catheter ablation outcomes of patients with long-standing persistent atrial fibrillation. Europace. 2014;16(6):848–54.

16. Deferm S, Bertrand PB, Verbrugghe FH, Verhaert D, Rega F, Thomas JD, Vanderveort PM. Atrial Functional Mitral Regurgitation: JACC review topic of the week. J Am Coll Cardiol. 2019;73(19):2465–76.

17. Corradi D, Callegari S, Maestrini R, Ferrara D, Mangieri D, Alinovi R, Mozzi P, Pinelli S, Goldoni M, Privitera YA, et al. Differential structural remodeling of the left-atrial posterior wall in patients affected by mitral regurgitation with or without persistent atrial fibrillation: a morphological and molecular study. J Cardiovasc Electrophysiol. 2012;23(3):271–9.

18. Praj D. Mitral Regurgitation, atrial fibrillation, and transcatheter mitral valve repair. JACC Cardiovasc Interv. 2019;12(6):579–81.

19. Frost L, Vukelic Andersen L, Godtfredsen J, Mortensen LS. Age and risk of stroke in atrial fibrillation: evidence for guidelines? Neuroepidemiology. 2007;28(2):109–15.

20. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

21. Brehmth K, Allen LA, Udelson J, Davis G, Bristow M. Changes in left ventricular ejection fraction predict survival and hospitalization in heart
failure with reduced ejection fraction. Circ Heart Fail. 2016. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002962.

22. Janwanidtaphorn S, Feng S, Teerlink J, Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Pang P, Ponikowski P, et al. Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. Eur J Heart Fail. 2020;22(4):726–38.